Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2004-12-6
pubmed:abstractText
In this study, the effect of leukemia inhibitory factor (LIF) on cisplatin (CDDP)-induced neuropathy was evaluated. Mice were treated with CDDP, 2 mg/kg i.p. twice a week nine times. During the last week some of the mice were also injected with LIF, 2 mug/kg s.c. every other day for a total of four injections. Development of neuropathy was evaluated with changes in tail flick latency and sensory nerve conduction velocity (NCV). At the end of the treatment period dorsal root ganglia (DRG) were microscopically examined. Some of the DRGs were explanted into extracellular matrix, covered with culture medium and incubated for 3 days. During and at the end of the incubation, cellular migration and axonal outgrowth from the DRGs were quantified. LIF proved effective in reversing the increase in tail flick latency (p<0.05) and improving the reduction in NCV induced by CDDP. CDDP led to smaller nuclear and somatic size in neurons, while with LIF, the latter was restored to control values (p<0.01). No apoptotic nucleus was observed among DRG neurons while very few and moderate numbers detected among satellite and Schwann cells, respectively. With LIF, none of the cells had apoptosis. CDDP caused a decrease in the number of migrating cells and in the length of outgrowing axons while LIF treatment restored both capacities (p<0.05) In conclusion, in CDDP-induced neuropathy, LIF was found to be effective in correcting some functional and morphological deteriorations related with major involvement of Schwann cells.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1043-4666
pubmed:author
pubmed:issnType
Print
pubmed:day
7
pubmed:volume
29
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
31-41
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15579376-Analysis of Variance, pubmed-meshheading:15579376-Animals, pubmed-meshheading:15579376-Apoptosis, pubmed-meshheading:15579376-Axons, pubmed-meshheading:15579376-Cell Movement, pubmed-meshheading:15579376-Cisplatin, pubmed-meshheading:15579376-Cross-Linking Reagents, pubmed-meshheading:15579376-Culture Media, pubmed-meshheading:15579376-Disease Models, Animal, pubmed-meshheading:15579376-Extracellular Matrix, pubmed-meshheading:15579376-Female, pubmed-meshheading:15579376-Ganglia, Spinal, pubmed-meshheading:15579376-In Situ Nick-End Labeling, pubmed-meshheading:15579376-Interleukin-6, pubmed-meshheading:15579376-Leukemia Inhibitory Factor, pubmed-meshheading:15579376-Mice, pubmed-meshheading:15579376-Neurons, pubmed-meshheading:15579376-Peripheral Nervous System Diseases, pubmed-meshheading:15579376-Schwann Cells, pubmed-meshheading:15579376-Time Factors
pubmed:year
2005
pubmed:articleTitle
Effect of leukemia inhibitory factor in experimental cisplatin neuropathy in mice.
pubmed:affiliation
Department of Physiology, Neuroscience Research Unit, Medical School, Yüzüncü Yil University, Fizyoloji ABD, 65200 Van, Turkey. drgurkan@yyu.edu.tr
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't